Robert, C. et al. Pembrolizumab versus ipilimumab in innovative cancer malignancy. N. Engl. J. Drug. 372 , 2521– 2532 (2015
Brief write-up
PubMed
Google Scholar
Wolchok, J. D. et al. General survival with combined nivolumab and ipilimumab in innovative cancer cells hatred. N. Engl. J. Medication. 377 , 1345– 1356 (2017
Short Article
PubMed
PubMed Central
Google Scholar
Ribas, A. et al. Company of pembrolizumab with growth responses and survival among individuals with innovative cancer malignancy. JAMA 315 , 1600– 1609 (2016
Review
PubMed
Google Scholar
Bagchi, S., Yuan, R. & & Engleman, E. G. Immune checkpoint avoidances for the treatment of cancer cells: expert impact and systems of activity and resistance. Annu. Rev. Pathol. 16 , 223– 249 (2021
Blog Post
PubMed
Google Scholar
Balch, C. M. et al. A multifactorial examination of cancer malignancy. IV. Prognostic consider 200 cancer cells hatred people with far-off metastases (stage III). J. Clin. Oncol. 1 , 126– 134 (2016
Short Article
Google Scholar
De Martin, E. et al. Characterization of liver injury brought on by cancer cells immunotherapy utilizing immune checkpoint preventions. J. Hepatol. 68 , 1181– 1190 (2018
Blog Post
PubMed
Google Scholar
Giaccone, G. et al. Pembrolizumab in customers with thymic cancer: a single-arm, single-centre, phase 2 study. Lancet Oncol. 19 , 347– 355 (2018
Brief write-up
PubMed
PubMed Central
Google Scholar
Adam, K., Iuga, A., Tocheva, A. S. & & Mor, A. A distinct computer mouse design for checkpoint inhibitor-induced unfavorable occasions. PLoS ONE 16 , e 0246168 (2021
Blog Post
PubMed
PubMed Central
Google Scholar
Langer, C. J. et al. Carboplatin and pemetrexed with or without pembrolizumab for innovative, non-squamous non-small-cell lung cancer cells: a randomised, stage 2 friend of the open-label KEYNOTE- 021 study. Lancet Oncol. 17 , 1497– 1508 (2016
Short Article
PubMed
PubMed Central
Google Scholar
Shui, L. et al. Bispecific antibodies: unleashing a new age in oncology therapy. Mol. Cancer Cells 24 , 212 (2025
Short Article
PubMed
PubMed Central
Google Scholar
Wang, C., Ye, Y., Hochu, G. M., Sadeghifar, H. & & Gu, Z. Improved cancer cells immunotherapy by microneedle patch-assisted circulation of anti-PD 1 antibody. Nano Lett. 16 , 2334– 2340 (2016
Brief write-up
PubMed
Google Scholar
Gilardi, M. et al. Microneedle-mediated intratumoral shipment of anti-CTLA- 4 promotes cDC 1- reliant removal of oral squamous cell cancer with very little irAEs. Mol. Cancer cells Ther. 21, 616– 624 (2022
Review
PubMed
PubMed Central
Google Scholar
Mikhail, A. S. et al. Hydrogel medicine circulation systems for minimally intrusive neighborhood immunotherapy of cancer cells. Adv. Medication Deliv. Rev. 202 , 115083 (2023
Short Article
PubMed
PubMed Central
Google Scholar
Jin, Q. et al. Nanoparticle-mediated circulation of breathed in immunotherapeutics for dealing with lung transition.(* )Adv. Mater. 33 , e 2007557 (2021 Review
PubMed
Google Scholar
Luke, J. J., Bao, R., Sweis, R. F., Spranger, S. & & Gajewski, T. F. WNT/ β-catenin path activation associates with immune exemption throughout human cancers cells.
Clin. Cancer cells Res. 25 , 3074– 3083 (2019 Blog Post
PubMed
PubMed Central
Google Scholar
Spranger, S., Bao, R. & & Gajewski, T. F. Melanoma-intrinsic β-catenin signalling safeguards versus anti-tumour resistance.
Nature 523 , 231– 235 (2015 Review
PubMed
Google Scholar
Waaler, J. et al. Tankyrase restriction animates cancer cells hatred to PD- 1 immune checkpoint clog in syngeneic computer mouse versions.
Commun. Biol. 3 , 196 (2020 Review
PubMed
PubMed Central
Google Scholar
DeVito, N. C. et al. Medical Wnt ligand restraint conquers crucial tumor-mediated resistance courses to anti-PD- 1 immunotherapy.
Cell Rep. 35 , 109071 (2021 Review
PubMed
PubMed Central
Google Scholar
Rodon, J. et al. Stage 1 study of single-agent WNT 974, a first-in-class porcupine avoidance, in people with innovative strong tumors.
Br. J. Cancer Cells 125 , 28– 37 (2021 Brief write-up
PubMed
PubMed Central
Google Scholar
Ruby, J. R. et al. Stage Ib expert test of the anti-Frizzled antibody vantictumab (OMP- 18 R 5 plus paclitaxel in customers with in your location advanced or metastatic HER 2 -unfavorable breast cancer cells.
Breast Cancer Cells Cells Res. Take care of. 184 , 53– 62 (2020 Short Article
PubMed
PubMed Central
Google Scholar
Kahn, M. Can we securely target the WNT path.
Nat. Rev. Medication Discov. 13 , 513– 532 (2014 Review
PubMed
PubMed Central
Google Scholar
Battistoni, A. et al. Nasal management of recombinant
Neospora caninum producing IL- 15/ IL- 15 Rα avoids metastatic cancer malignancy development in lung. J. Immunother. Cancer cells 11 , e 006683 (2023 Wang, Z. et al. Exosomes boosted with a recombinant SARS-CoV- 2 receptor-binding domain as an inhalable COVID- 19 vaccination.
Nat. Biomed. Eng 6 , 791– 805 (2022 Blog Post
PubMed
PubMed Central
Google Scholar
Popowski, K. D. et al. Inhalable totally dry powder mRNA inoculations based upon extracellular sores.
Problem 5 , 2960– 2974 (2022 Short Article
PubMed
PubMed Central
Google Scholar
Liu, M., Hu, S., Yan, N., Popowski, K. D. & & Cheng, K. Inhalable extracellular sore delivery of IL- 12 mRNA to deal with lung cancer cells and market systemic resistance.
Nat. Nanotechnol. 19 , 565– 575 (2024 Dinh, P.-U. C. et al. Breathing of lung spheroid cell secretome and exosomes promotes lung repair work solution in lung fibrosis.
Nat. Commun. 11 , 1064 (2020 Short Article
PubMed
PubMed Central
Google Scholar
Zhang, S. W., Edwards, D. A., Langer, R. & & Cheng, K. Inhalable items and biologics for lung assistance and medicine shipment.
Nat. Rev. Mater. https://doi.org/ 10 1038/ s 41578 – 025 – 00841 -y (2025 Cheng, K. & & Kalluri, R. Standards for scientific translation and commercialization of extracellular sores and exosomes based rehabs.
Extracell. Ves. 2 , 100029 (2023 Zickler, A. M. & & El Andaloussi, S. Useful extracellular blisters aplenty.
Nat. Biomed. Eng 4 , 9– 11 (2020 Review
PubMed
Google Scholar
Rayamajhi, S. & & Aryal, S. Area functionalization techniques of extracellular sores.
J. Mater. Chem. B 8 , 4552– 4569 (2020 Blog Post
PubMed
Google Scholar
Gupta, D. et al. Amelioration of systemic swelling through the display screen of 2 various decoy healthy protein receptors on extracellular blisters.
Nat. Biomed. Eng 5 , 1084– 1098 (2021 Short Article
PubMed
Google Scholar
Dooley, K. et al. A flexible system for developing crafted extracellular blisters with defined healing homes.
Mol. Ther. 29 , 1729– 1743 (2021 Short Article
PubMed
PubMed Central
Google Scholar
Jeppesen, D. K. et al. Review of exosome makeup.
Cell 177 , 428– 445 (2019 Blog Post
PubMed
PubMed Central
Google Scholar
Kugeratski, F. G. et al. Quantifiable proteomics identifies the core proteome of exosomes with syntenin- 1 as the best bountiful healthy protein and a suppositious global biomarker.
Nat. Cell Biol. 23 , 631– 641 (2021 Review
PubMed
PubMed Central
Google Scholar
Simpson, R. J., Kalra, H. & & Mathivanan, S. ExoCarta as a resource for exosomal research.
J. Extracell. Blisters 1 , 18374 (2012 Lee, K. M., Seo, E. C., Lee, J. H., Kim, H. J. & & Hwangbo, C. The multifunctional healthy protein syntenin- 1: regulatory authority of exosome biogenesis, mobile function, and growth advancement.
Int. J. Mol. Sci. 24 , 9418 (2023 Hurley, J. H. & & Odorizzi, G. Get on the exosome bus with ALIX.
Nat. Cell Biol. 14 , 654– 655 (2012 Review
PubMed
Google Scholar
Li, S. P., Lin, Z. X., Jiang, X. Y. & & Yu, X. Y. Exosomal cargo-loading and artificial exosome-mimics as possible corrective gadgets.
Acta Pharmacol. Incorrect. 39 , 542– 551 (2018 Brief write-up
PubMed
PubMed Central
Google Scholar
Marquez-Rodas, I. et al. Immune checkpoint preventions: corrective improvements in cancer cells hatred.
Ann. Transl. Medicine. 3 , 267 (2015 PubMed
PubMed Central
Google Scholar
Carlino, M. S., Larkin, J. & & Long, G. V. Immune checkpoint preventions in cancer cells hatred.
Lancet 398 , 1002– 1014 (2021 Short Article
PubMed
Google Scholar
Harlin, H. et al. Chemokine expression in cancer malignancy metastases gotten in touch with CD 8
+ T-cell work. Cancer cells Res. 69 , 3077– 3085 (2009 Brief write-up
PubMed
Google Scholar
Ji, R.-R. et al. An immune-active swelling microenvironment likes clinical response to ipilimumab.
Cancer cells Immunol. Immunother. 61 , 1019– 1031 (2012 Review
PubMed
Google Scholar
Hugo, W. et al. Genomic and transcriptomic functions of activity to anti-PD- 1 therapy in metastatic cancer cells hatred.
Cell 165 , 35– 44 (2016 Brief write-up
PubMed
PubMed Central
Google Scholar
Li, Y. et al. N-Myc downstream-regulated genetics 2, an unique estrogen-targeted genetics, is related to the standard of Na
+ / K + -ATPase. J. Biol. Chem. 286 , 32289– 32299 (2011 Short Article
PubMed
PubMed Central
Google Scholar
Khuu, C. H., Barrozo, R. M., Hai, T. & & Weinstein, S. L. Turning on transcription component 3 (ATF 3 quelches the expression of CCL 4 in murine macrophages.
Mol. Immunol. 44 , 1598– 1605 (2007 Short Article
PubMed
Google Scholar
Anderson, K. G., Stromnes, I. M. & & Greenberg, P. D. Obstacles placed by the swelling microenvironment to T cell task: a circumstances for collaborating therapies.
Cancer cells Cell 31 , 311– 325 (2017 Short Article
PubMed
PubMed Central
Google Scholar
Spranger, S., Dai, D., Horton, B. & & Gajewski, T. F. Tumor-residing BATF 3 dendritic cells are required for effect T cell trafficking and adoptive T cell therapy.
Cancer Cells Cell 31 , e 714 (2017 Short Article
Google Scholar
Reschke, R. et al. Immune cell and swelling cell-derived CXCL 10 is a measure of immunotherapy responses in metastatic cancer malignancy.
J. Immunother. Cancer Cells 9 , e 003521 (2021 Padovan, E., Spagnoli, G. C., Ferrantini, M. & & Heberer, M. IFN-α 2 a generates IP- 10/ CXCL 10 and MIG/CXCL 9 production in monocyte-derived dendritic cells and improves their ability to generate and advertise CD 8
+ result T cells. J. Leukoc. Biol. 71 , 669– 676 (2002 Short Article
PubMed
Google Scholar
Chen, G. et al. Exosomal PD-L 1 adds to immunosuppression and relates to anti-PD- 1 responses.
Nature 560 , 382– 386 (2018 Review
PubMed
PubMed Central
Google Scholar
Poggio, M. et al. Decreases of exosomal PD-L 1 causes systemic anti-tumor resistance and memory.
Cell 177 , 414– 427 (2019 Blog Post
PubMed
PubMed Central
Google Scholar
Yang, Y. et al. Exosomal PD-L 1 nurtures energised security function to restrain T cell murder of bust cancer cells and market growth advancement.
Cell Res. 28 , 862– 864 (2018 Short Article
PubMed
PubMed Central
Google Scholar
Janda, C. Y., Waghray, D., Levin, A. M., Thomas, C. & & Garcia, K. C. Structural basis of Wnt recommendation by Frizzled.
Scientific study 337 , 59– 64 (2012 Review
PubMed
PubMed Central
Google Scholar
Woo, S. R. et al. Immune repressive particles LAG- 3 and PD- 1 synergistically take care of T-cell function to market tumoral immune hideaway.
Cancer cells Res. 72 , 917– 927 (2012 Brief write-up
PubMed
Google Scholar
Peng, W. et al. PD- 1 blockage increases T-cell activity to swellings by elevating IFN-γ inducible chemokines.
Cancer cells Res. 72 , 5209– 5218 (2012 Review
PubMed
PubMed Central
Google Scholar
Fuertes, M. B. et al. Host kind I IFN signals are required for antitumor CD 8
+ T cell comments with CD 8 α + dendritic cells. J. Exp. Medication. 208 , 2005– 2016 (2011 Short Article
PubMed
PubMed Central
Google Scholar
Corso, G. et al. Organized characterization of extracellular blister sorting domain and metrology at the singular bit– singular sore level by fluorescence partnership spectroscopy and singular little bit imaging.
J. Extracell. Sores 8 , 1663043 (2019 Short Article
PubMed
PubMed Central
Google Scholar
Parsons, M. J., Tammela, T. & & Dow, L. E. WNT as a car motorist and dependancy in cancer cells.
Cancer Cells Discov. 11 , 2413– 2429 (2021 Brief write-up
PubMed
PubMed Central
Google Scholar
Gajos-Michniewicz, A. & & Czyz, M. WNT signaling in cancer malignancy.
Int. J. Mol. Sci. 21 , 4852 (2020 Li, S. et al. PIF 1 helicase promotes break-induced replication in pet cells.
EMBO J. 40 , e 104509 (2021 Review
PubMed
PubMed Central
Google Scholar
Thery, C. et al. Extremely little information for investigates of extracellular sores 2018 (MISEV 2018: a positioning declaration of the International Culture for Extracellular Sores and upgrade of the MISEV 2014 criteria.
J. Extracell. Blisters 7 , 1535750 (2018 Short Article
PubMed
PubMed Central
Google Scholar
McDermott, S. P., Eppert, K., Lechman, E. R., Doedens, M. & & Penis, J. E. Comparison of human cable blood engraftment in between immunocompromised computer mouse stress and anxiety.
Blood 116 , 193– 200 (2010 Blog Post
PubMed
Google Scholar
Liu, S. et al. DNA repair service healthy and balanced protein RAD 52 is needed for securing G-quadruplexes in pet cells.
J. Biol. Chem. 299 , 102770 (2023 Blog Post
PubMed
Google Scholar
Zhenilo, S. et al. DeSUMOylation switches over Kaiso from activator to repressor upon hyperosmotic stress.
Cell Fatality Differ. 25 , 1938– 1951 (2018 Review
PubMed
PubMed Central
Google Scholar
Liu, S. et al. FZR 1 as a distinct biomarker for breast cancer cells neoadjuvant radiation therapy projection.
Cell Fatality Dis. 11 , 804 (2020 Short Article
PubMed
PubMed Central
Google Scholar
Hugo W. et al. mRNA expressions in pre-treatment cancer malignancies undergoing anti-PD- 1 checkpoint restriction therapy.
Genes Expression Omnibus https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE 78220 (2016 Evaluation the complete article from the initial resource
